SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
We are inviting young people aged 16 to 25 years, with moderate-to-severe depression, to take part in this research. Participants will divided into two groups. One group will receive a low dose of ketamine once a week for four weeks. The other group will receive a low dose of another medication, called midazolam, once a week for four weeks.
We hope that the results of this study will help us to provide the best possible care in the future for young people with depression.
The purpose of this study is to compare the effects, good or bad, of combination immunotherapy (atezolizumab plus bevacizumab) versus observation (not receiving any treatment) on participants with completely resected or ablated hepatocellular cancer (HCC) who are at high risk for disease recurrence. In this study, patients will receive either atezolizumab plus bevacizumab or no treatment.